These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20505537)

  • 1. A desensitization protocol in children with L-asparaginase hypersensitivity.
    Akbayram S; Doğan M; Akgün C; Caksen H; Oner AF
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):e187-91. PubMed ID: 20505537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
    Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
    J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
    Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
    Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
    Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
    Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
    Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
    Larson RA; Fretzin MH; Dodge RK; Schiffer CA
    Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
    Sikorska-Fic B; Makowska K; Rokicka-Milewska R
    Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic.
    Morimoto A; Imamura T; Ishii R; Nakabayashi Y; Nakatani T; Sakagami J; Yamagami T
    Cancer; 2008 Sep; 113(6):1362-9. PubMed ID: 18661511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
    Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
    Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
    Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
    Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
    Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated
    Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
    Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia.
    Cetin M; Yetgin S; Kara A; Tuncer AM; Günay M; Gümrük F; Gürgey A
    J Med; 1994; 25(3-4):219-29. PubMed ID: 7996065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
    Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
    Appel IM; Hop WC; Pieters R
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.